Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solrikitug in COPD
NCT06496620Phase 2Active, not recruiting
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of solrikitug in chronic obstructive pulmonary disease (COPD) (3 arms). Primary endpoint: Change from baseline in blood eosinophil counts at 12 weeks. Started Aug 2024; status: active, not recruiting.
02
Drugs
solrikitug
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06496620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496620.